Oxabolone cipionate
| Clinical data | |
|---|---|
| Trade names | Steranabol Depo, Steranabol Ritardo |
| Other names | Oxabolone cypionate; FI-5852; 4-Hydroxy-19-nortestosterone 17β-cypionate; Estr-4-en-4,17β-diol-3-one 17β-cypionate |
| Routes of administration | Intramuscular injection |
| Drug class | Androgen; Anabolic steroid; Androgen ester |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.013.647 |
| Chemical and physical data | |
| Formula | C26H38O4 |
| Molar mass | 414.586 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Oxabolone cipionate (INN, JAN) (brand names Steranabol Depo, Steranabol Ritardo; former developmental code name FI-5852), or oxabolone cypionate, also known as 4-hydroxy-19-nortestosterone 17β-cypionate or estr-4-en-4,17β-diol-3-one 17β-cypionate, is synthetic and injected anabolic–androgenic steroid (AAS) and derivative of nandrolone (19-nortestosterone) which has been marketed in Europe. It is the C17β cypionate ester and a prodrug of oxabolone (4-hydroxy-19-nortestosterone).